11363 related articles for article (PubMed ID: 11251950)
1. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
2. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
5. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
[TBL] [Abstract][Full Text] [Related]
6. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma.
Murali R; Hughes MT; Fitzgerald P; Thompson JF; Scolyer RA
Ann Surg; 2009 Apr; 249(4):641-7. PubMed ID: 19300224
[TBL] [Abstract][Full Text] [Related]
7. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic study of recurrent Clark level II melanomas.
Glass LF; Guffey JM; Schroer KR; Reintgen D
Semin Surg Oncol; 1993; 9(3):202-7. PubMed ID: 8516604
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness.
Morton DL; Davtyan DG; Wanek LA; Foshag LJ; Cochran AJ
Cancer; 1993 Jun; 71(11):3737-43. PubMed ID: 8490924
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
11. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system.
Finley JW; Gibbs JF; Rodriguez LM; Letourneau R; Driscoll D; Kraybill W
Am Surg; 2000 Jun; 66(6):527-31; discussion 531-2. PubMed ID: 10888127
[TBL] [Abstract][Full Text] [Related]
12. Depth of invasion and tumor thickness in primary cutaneous malignant melanoma. A study of 2012 cases.
Søndergaard K
Acta Pathol Microbiol Immunol Scand A; 1985 Mar; 93(2):49-55. PubMed ID: 3984735
[TBL] [Abstract][Full Text] [Related]
13. Contemporary surgical treatment of advanced-stage melanoma.
Essner R; Lee JH; Wanek LA; Itakura H; Morton DL
Arch Surg; 2004 Sep; 139(9):961-6; discussion 966-7. PubMed ID: 15381613
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
15. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
Crocetti E; Mangone L; Lo Scocco G; Carli P
Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
[TBL] [Abstract][Full Text] [Related]
16. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.
Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U; Wagenius G;
Cancer; 2004 Nov; 101(9):2067-78. PubMed ID: 15372475
[TBL] [Abstract][Full Text] [Related]
17. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Gimotty PA; Botbyl J; Soong SJ; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
[TBL] [Abstract][Full Text] [Related]
18. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
19. [Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].
Eigentler TK; Radny P; Kamin A; Weide B; Caroli UM; Garbe C
J Dtsch Dermatol Ges; 2005 Aug; 3(8):592-8. PubMed ID: 16033477
[TBL] [Abstract][Full Text] [Related]
20. Population-based analysis of prognostic factors and survival in familial melanoma.
Florell SR; Boucher KM; Garibotti G; Astle J; Kerber R; Mineau G; Wiggins C; Noyes RD; Tsodikov A; Cannon-Albright LA; Zone JJ; Samlowski WE; Leachman SA
J Clin Oncol; 2005 Oct; 23(28):7168-77. PubMed ID: 16192601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
